{"id":3746,"date":"2021-05-06T18:50:00","date_gmt":"2021-05-06T16:50:00","guid":{"rendered":"https:\/\/ibtherapeutics.com\/sv\/mfn_news\/vds-anforande-i-samband-med-infant-bacterial-therapeutics-arsstamma\/"},"modified":"2023-10-02T13:51:40","modified_gmt":"2023-10-02T11:51:40","slug":"vds-anforande-i-samband-med-infant-bacterial-therapeutics-arsstamma","status":"publish","type":"mfn_news","link":"https:\/\/ibtherapeutics.com\/sv\/pressmeddelanden\/vds-anforande-i-samband-med-infant-bacterial-therapeutics-arsstamma\/","title":{"rendered":"VDs anf\u00f6rande i samband med Infant Bacterial Therapeutics \u00e5rsst\u00e4mma"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<div>\n<p>Verkst\u00e4llande direkt\u00f6ren Staffan Str\u00f6mbergs anf\u00f6rande i samband med IBTs \u00e5rsst\u00e4mma 2021 kan ses <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZUCAArluFjDVKwC-lC21h6kX4LhPtIoEhUB-9JAHdSAe1NBn-MZnm4QdB0rb11YgduzHSU-JUQlGbWIdSjMBzQtW8s56am31b9MD_0Ed_st7vOKH_plQIE4b1odg4wBC\" target=\"_blank\" title=\"h\u00e4r\" rel=\"nofollow noopener\">h\u00e4r<\/a>\u00a0\u00a0<\/p>\n<p><strong><em>Om Infant Bacterial Therapeutics AB<\/em><\/strong><\/p>\n<p>Infant Bacterial Therapeutics AB (publ) (\u201cIBT\u201d) \u00e4r ett l\u00e4kemedelsf\u00f6retag med en produkt i klinisk utvecklings fas III, vars vision \u00e4r att utveckla l\u00e4kemedel som p\u00e5verkar sp\u00e4dbarns mikrobiom och d\u00e4rigenom kunna f\u00f6rebygga eller behandla s\u00e4llsynta sjukdomar som drabbar sp\u00e4dbarn.<\/p>\n<p>IBT \u00e4r f\u00f6r n\u00e4rvarande inriktat p\u00e5 att utveckla l\u00e4kemedelskandidaten IBP-9414 som syftar till att f\u00f6rebygga nekrotiserande enterokolit (\u201dNEC\u201d) samt att f\u00f6rb\u00e4ttra s\u00e5 kallad <em>feeding<\/em> <em>tolerance<\/em> hos f\u00f6r tidigt f\u00f6dda barn. IBP-9414 inneh\u00e5ller <em>Lactobacillus reuteri<\/em> som aktiv substans, vilket \u00e4r en human bakteriestam som \u00e5terfinns naturligt i br\u00f6stmj\u00f6lk. I portf\u00f6ljen finns \u00e4ven ett ytterligare projekt, IBP-1016, f\u00f6r behandling av gastroschisis, en allvarlig och s\u00e4llsynt sjukdom som drabbar sp\u00e4dbarn. Genom utvecklingen av dessa l\u00e4kemedel har IBT m\u00f6jlighet att tillfredsst\u00e4lla medicinska behov d\u00e4r det idag inte finns n\u00e5gra tillg\u00e4ngliga behandlingar.<\/p>\n<p>Infant Bacterial Therapeutics AB (\u201dIBT\u201d) \u00e4r ett publikt bolag med s\u00e4te i Stockholm. Bolagets aktier av serie B handlas pa\u030a Nasdaq Stockholm, Mid Cap (IBT B).<\/p>\n<p><strong>F\u00f6r mer information, v\u00e4nligen kontakta <\/strong><\/p>\n<p>Staffan Str\u00f6mberg, VD<br \/>Daniel Mackey CFO<br \/>Infant Bacterial Therapeutics AB<br \/>Bryggargatan 10<br \/>111 21 Stockholm<br \/>Telefon: +46 70 670 1226<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jSDsgV_EvV4pP39hEFRhQdU7w9dpsnqxxWFJ9F3MYYPtStjV3-FKMfOPx2V3HcPNjh5nPhAZZygDdxG0H2ViaPKE418uC-Q-3RBVTTik0Oc=\" target=\"_blank\" rel=\"nofollow noopener\">info@ibtherapeutics.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zvQseum44YgegbO5sXfcEZMdiTBlnfH80v16GmIrXsbZEDEQkNND-tHC0_AdrIt4W7o24RKuBdkBG-dfQOn_iimFYTqlOYrXfI1bb7aK7TM=\" target=\"_blank\" title=\"www.ibtherapeutics.com\" rel=\"nofollow noopener\">www.ibtherapeutics.com<\/a><\/p>\n<\/p>\n<p>\n        <\/div>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1cf5977c-669e-4cd9-96ad-34f6c6e429cf\" target=\"_blank\" rel=\"nofollow noopener\">PR 20210506 AGM SWE video<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment\"><a class=\"mfn-attachment-link\" href=\"https:\/\/storage.mfn.se\/proxy\/pr-20210506-agm-swe-video.pdf?url=https%3A%2F%2Fml-eu.globenewswire.com%2FResource%2FDownload%2F1cf5977c-669e-4cd9-96ad-34f6c6e429cf\"><span class=\"mfn-attachment-icon\"><img alt=\"VDs anf\u00f6rande i samband med Infant Bacterial Therapeutics \u00e5rsst\u00e4mma\" src=\"https:\/\/storage.mfn.se\/proxy\/pr-20210506-agm-swe-video.pdf?url=https%3A%2F%2Fml-eu.globenewswire.com%2FResource%2FDownload%2F1cf5977c-669e-4cd9-96ad-34f6c6e429cf&type=jpg\"><\/span>PR 20210506 AGM SWE video<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Verkst\u00e4llande direkt\u00f6ren Staffan Str\u00f6mbergs anf\u00f6rande i samband med IBTs \u00e5rsst\u00e4mma 2021 kan ses h\u00e4r\u00a0\u00a0 Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) (\u201cIBT\u201d) \u00e4r ett l\u00e4kemedelsf\u00f6retag med en produkt i klinisk utvecklings fas III, vars vision \u00e4r att utveckla l\u00e4kemedel som p\u00e5verkar sp\u00e4dbarns mikrobiom och d\u00e4rigenom kunna f\u00f6rebygga eller behandla s\u00e4llsynta sjukdomar som [&hellip;]<\/p>\n","protected":false},"template":"","_links":{"self":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3746"}],"collection":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=3746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}